Culmerciclib（Cat No.:I043413）is a selective inhibitor of cyclin-dependent kinase 7 (CDK7), a key enzyme that regulates transcription and cell cycle progression. By inhibiting CDK7, Culmerciclib blocks the phosphorylation of RNA polymerase II, reducing the transcription of genes critical for cancer cell proliferation and survival. It has shown promise in preclinical studies as a potential treatment for various cancers, including those resistant to other therapies. Culmerciclib’s ability to selectively target CDK7 offers a novel therapeutic strategy to disrupt the transcriptional machinery in cancer cells, potentially enhancing the efficacy of existing treatments.